Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States

By afschroeder • November 15, 2025

Charles-Schoeman C, Zueger P, McDearmon-Blondell E, Fang S, Peng Y, Oishi T, Jain M, Tesser J. Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States. Rheumatol Ther. 2025 Nov 14. doi: 10.1007/s40744-025-00808-z. Epub ahead of print. PMID: 41239038.

Tags: Biologic disease-modifying antirheumatic drug(bDMARD), Clinical Disease Activity Index(CDAI), Publications, Rheumatoid arthritis(RA), Rheumatology, Tumor necrosis factor inhibitor(TNFi)

Primary Care Practice Productivity and Efficiency: Qualitative Evaluation of a Novel Clinic-Based Measure

McCleskey SG, Khodyakov D, Nelson KM, Curtis I, Newberry SJ, Tran LD, Fihn SD, Wagner TH, Rubenstein LV. Primary Care Practice Productivity and Efficiency: Qualitative[...]

Impact of a stigma-disrupting addiction medicine core curriculum on internal medicine resident attitudes and preparedness: results from a pilot study

Lawrence D, Marshall KF. Impact of a stigma-disrupting addiction medicine core curriculum on internal medicine resident attitudes and preparedness: results from a pilot study. BMC[...]

Decade Growing in Plain Sight: Detection of an Invasive Melanoma Within a Long-Standing Pigmented Lesion

Freeman M, Gates G, Ahronowitz I. Decade Growing in Plain Sight: Detection of an Invasive Melanoma Within a Long-Standing Pigmented Lesion. Cureus. 2026 Oct 10;18(10):e117734.[...]